IMNN-001 is under clinical development by Imunon and currently in Phase II for Epithelial Tumor. According to GlobalData, Phase II drugs for Epithelial Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IMNN-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMNN-001 overview
GEN-1 (EGEN-001) is under development for the treatment of epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, high-grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma and mixed epithelial carcinoma. It is administered intraperitoneally. The therapeutic candidate comprises DNA plasmid encoding IL-12 p35 and p40 genes. It is developed based on the TheraPlas delivery technology, an IL-12 DNA nucleic acid plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein.
It was also under development for colorectal cancer and glioblastoma multiforme (brain cancer).
Imunon overview
Imunon, formerly Celsion is a clinical-stage oncology company with a focus on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA and DNA based therapies and immunotherapies. The company develops drugs using its three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), TheraPlas and TheraSilence. Its lead product candidate ThermoDox is a proprietary form of doxorubicin based LTSL technology in Phase III clinical trial for the treatment of primary liver cancer. It is also developing a pipeline of targeted therapeutic agents for cancer. Imunon is headquartered in Lawrenceville, New Jersey, the US.
For a complete picture of IMNN-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
